Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003
- 10 August 2004
- journal article
- Published by Wiley in Tropical Medicine & International Health
- Vol. 9 (8), 923-927
- https://doi.org/10.1111/j.1365-3156.2004.01281.x
Abstract
Objective Ribavirin is a broad spectrum nucleoside analogue efficacious in the treatment of several viral infections. In the recent severe acute respiratory syndrome (SARS) outbreak, ribavirin was used in various countries against this novel coronavirus. We conducted a retrospective analysis to assess the efficacy of ribavirin in the treatment of SARS in Singapore.Keywords
This publication has 10 references indexed in Scilit:
- Do Men Have a Higher Case Fatality Rate of Severe Acute Respiratory Syndrome than Women Do?American Journal of Epidemiology, 2004
- Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in CanadaClinical Infectious Diseases, 2003
- Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysisBMJ, 2003
- Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto AreaPublished by American Medical Association (AMA) ,2003
- A Major Outbreak of Severe Acute Respiratory Syndrome in Hong KongNew England Journal of Medicine, 2003
- A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong KongNew England Journal of Medicine, 2003
- Development of a standard treatment protocol for severe acute respiratory syndromeThe Lancet, 2003
- Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective studyThe Lancet, 2003
- Severe acute respiratory syndrome (SARS) and coronavirus testing--United States, 2003.2003
- Ribavirin Inhibits Viral-Induced Macrophage Production of TNF, IL-1, the Procoagulant fgl2 Prothrombinase and Preserves Th1 Cytokine Production But Inhibits Th2 Cytokine ResponseThe Journal of Immunology, 1998